the purpose of securing the 10 Million in funding,
was to fund the Phase 3 clinical trial in ARDS.
10 Million to get to the end results / the data from that trial , and then
it's either a partnership, licensing, a buyout, or treatments in clinics . These are several of the options i can come up with when they get to point B
so remember , it's the funding that was secured to get to point B .
i hope when the right time comes, we see better valuation, after that 10 million infusion.
It's bio, it's risky like everything else. there's always competition to get your products to the market in Bio.
News 
Market Data 
Discover 
AI
